News

Therapies to target geographic atrophy are in sight.

Francine Behar-Cohen, MD, PhD, presented the data at the Association for Research in Vision and Ophthalmology Annual Meeting in New Orleans.

Ophthalmology Times® talked with David Eveleth, MD, CEO and Founder of Trefoil Therapeutics about TTHX1114 in patients with Fuchs endothelial corneal dystrophy (FECD) undergoing Descemet’s Stripping Only (DSO) in combination with cataract surgery at this year's ARVO meeting.

Visual impairment is associated with hallucinations, depression, agitation, and psychosis in patients with dementia.

Grace Walther, first author of the study, described that lens centration on the eye may be beneficial for improving vision. Association for Research in Vision and Ophthalmology annual meeting.

Amir H. Kashani, MD, PhD, sat down with David Hutton, Managing Editor, Ophthalmology Times®, to discuss his presentation at this year's ARVO meeting on optical coherence tomography and the assessment of cognitive impairment in Alzheimer's Disease and other related dementias.

Ophthalmology Times® talked with Mark Bullimore and discussed the control of myopia progression with low-concentration atropine from the Hong-Kong LAMP study at this year's ARVO meeting.

Ophthalmology Times® talked with T. Y. Alvin Liu, MD, about predictive AI and its uses in ophthalmology and screening of the eyes at this year's ARVO meeting.

In a presentation during the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, being held at the Ernest N. Morial Convention Center in New Orleans, Luxa Biotechnology offered details of a clinical trial evaluating transplantation of cells derived from adult retinal pigmented epithelium stem cells to treat dry AMD.

According to the company, StableVisc and TotalVisc offer surgeons dual-action protection during cataract surgery.

In a presentation at the Association for Research in Vision and Ophthalmology Annual Meeting in New Orleans, data demonstrated the loss of retinal pigmented epithelial and photoreceptor cells, both of which are required for visual function.

According to data presented at the Association for Research in Vision and Ophthalmology Annual Meeting in New Orleans, post-hoc analysis from the GATHER trials, for the first time, signals that reduced rate of vision loss in patients receiving avacincaptad pegol was correlated with reduced geographic atrophy (GA) growth.

Pros and cons of anti-VEGF drugs and improved visualization of abnormalities in ROP.

Hydrogen water intake improved retinal blood flow (RBF) dysregulation in response to flicker stimulation and systemic hyperoxia in type 2 diabetic mice.

Thomas V. Johnson, MD, PhD, sat down with David Hutton, Managing Editor, Ophthalmology Times®, to discuss his presentation at this year's ARVO meeting on retinal engineering and RGC replacement.

Ophthalmology Times® talked with Caroline Baumal, MD, about Apellis' presentations focusing on visual function, imaging and artificial intelligence at this year's ARVO meeting.

Japanese investigators have found an ocular biomarker of cardiovascular diseases.

According to data presented at the Association for Research in Vision and Ophthalmology annual meeting in New Orleans, staggered administration of Ixo-vec in non-human primates showed peak aflibercept protein levels in the second eye within the targeted therapeutic range, supporting the potential for bilateral administration.

In a presentation at ARVO 2023 in New Orleans, the company noted data in a nonhuman primate model of non-arteritic anterior ischemic optic neuropathy demonstrates the ability to restore visual function after delivery of a novel gene therapy.

SB15 (Samsung Bioepis) has shown similar efficacy, pharmacokinetics, safety, immunogenicity to aflibercept after 56 Weeks in phase 3 clinical trial.

Ophthalmology Times® talked with Deborah Ferrington, PhD, about her presentation on using human donor tissue to identify the mechanism responsible for the death of the retinal pigment epithelium.

Ophthalmology Times® talked with Roland Mattern, Director of Sales and Marketing for eSight and eSight User Gary Foster at this year's ARVO meeting about eSight Go, the new model of smart glasses for low vision enhancement

Ophthalmology Times® talked with George Magrath, MD, and Andrew Pucker, OD, MS, PhD, FAAO at this year's ARVO meeting about Lexitas Pharma Services' work on modification of the National Eye Institute's corneal fluorescein staining scale.

The Association for Research in Vision and Ophthalmology (ARVO) kicked off its annual meeting today at the Ernest N. Morial Convention Center in New Orleans.

Defective calcium clearance is a characteristic feature of early damage to the retinal ganglion cells (RGC) in a mouse model of glaucoma.

Patrick Yu-Wai-Man, MD, PhD, is being recognized by the ARVO Foundation for his research on gene replacement therapy for Leber hereditary optic neuropathy.

Current smokers with Graves' Disease had a greater 5-year cumulative probability, compared with patients who had never smoked, of undergoing orbital decompression.

The endothelial cells play an essential role in vision. They ensure that the cornea remains transparent by keeping it partially dehydrated.

According to the companies, Boehringer Ingelheim will use RetinAI’s tools to develop treatments for GA, applying the company’s artificial intelligence tools to its imaging data in a search for novel biomarkers and predictors of disease progression.

Researchers at the Smurfit Institute of Genetics, in collaboration with the biotechnology company Exhaura Ltd., have shown that a gene therapy-based approach can decrease intraocular pressure in pre-clinical models of glaucoma.